SXT1596 is a novel inhibitor of the SS18-SSX/TLE1 interaction. SXT1596 decreases cell viability and reactivates EGR1 expression in synovial sarcoma. References: Laporte AN, Ji JX, Ma L, Nielsen TO, Brodin BA. Identification of cytotoxic agents disrupting synovial sarcoma oncoprotein interactions by proximity ligation assay. Oncotarget. 2016;7(23):34384-34394. doi:10.18632/oncotarget.8882.

纯度：≥98%

CAS：5438-41-5